Clinical Trial Update: Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF [Phase 3]

View source ↗

Summary

Phase 3 switch study evaluating F/TAF in HIV-1 patients virologically suppressed on regimens containing FTC/TDF has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• F/TAF (emtricitabine/tenofovir alafenamide)
• FTC/TDF (emtricitabine/tenofovir disoproxil fumarate)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2016-11-30